LON:UDG - UDG Healthcare Stock Price Target and Predictions

  • Consensus Rating: Hold
  • Consensus Price Target: GBX 1,000
  • Forecasted Upside:
  • Number of Analysts: 1
  • Breakdown:
  • 0 Sell Ratings
  • 1 Hold Ratings
  • 0 Buy Ratings
  • 0 Strong Buy Ratings
GBX 0
+0 (0.00%)

This chart shows the closing price for UDG by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New UDG Healthcare Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for UDG and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for UDG

Analyst Price Target is GBX 1,000
▲ +∞ Upside Potential
This price target is based on 1 analysts offering 12 month price targets for UDG Healthcare in the last 3 months. The average price target is GBX 1,000, with a high forecast of GBX 0 and a low forecast of GBX 0. The average price target represents a ∞ upside from the last price of GBX 0.

This chart shows the closing price for UDG for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart

Current Consensus is Hold

The current consensus among 1 polled investment analysts is to hold stock in UDG Healthcare. This Hold consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 2 buy ratings
  • 4 hold ratings
  • 0 sell ratings
1/9/2021
  • 0 strong buy ratings
  • 2 buy ratings
  • 3 hold ratings
  • 0 sell ratings
4/9/2021
  • 0 strong buy ratings
  • 0 buy ratings
  • 3 hold ratings
  • 0 sell ratings
7/8/2021
  • 0 strong buy ratings
  • 0 buy ratings
  • 3 hold ratings
  • 0 sell ratings
10/6/2021
  • 0 strong buy ratings
  • 0 buy ratings
  • 3 hold ratings
  • 0 sell ratings
1/4/2022
  • 0 strong buy ratings
  • 0 buy ratings
  • 3 hold ratings
  • 0 sell ratings
4/4/2022
  • 0 strong buy ratings
  • 0 buy ratings
  • 1 hold ratings
  • 0 sell ratings
6/3/2022
  • 0 strong buy ratings
  • 0 buy ratings
  • 1 hold ratings
  • 0 sell ratings
7/3/2022

Latest Recommendations

  • 0 strong buy ratings
  • 0 buy ratings
  • 1 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetDetails
7/29/2021BarclaysDowngradeEqual WeightGBX 975 ➝ GBX 1,000
5/24/2021Royal Bank of CanadaReiterated RatingSector PerformGBX 1,023
5/12/2021Royal Bank of CanadaDowngradeSector PerformGBX 940 ➝ GBX 1,023
5/12/2021Berenberg BankDowngradeHoldGBX 880 ➝ GBX 1,023
5/6/2021BarclaysBoost Price TargetOverweightGBX 920 ➝ GBX 975
9/1/2020Berenberg BankReiterated RatingBuyGBX 880
7/22/2020BarclaysReiterated RatingOverweight
7/3/2020Berenberg BankReiterated RatingBuy
7/2/2020Liberum CapitalReiterated RatingBuy
7/2/2020Peel HuntReiterated RatingBuy
6/15/2020Liberum CapitalReiterated RatingBuy
6/11/2020Peel HuntLower Price TargetBuyGBX 1,165 ➝ GBX 1,050
6/10/2020Royal Bank of CanadaDowngradeSector PerformerGBX 730 ➝ GBX 800
6/3/2020Peel HuntReiterated RatingBuy
6/3/2020BarclaysLower Price TargetOverweightGBX 910 ➝ GBX 875
5/20/2020Berenberg BankBoost Price TargetBuyGBX 740 ➝ GBX 880
5/19/2020Peel HuntReiterated RatingBuy
5/19/2020Liberum CapitalReiterated RatingBuy
5/8/2020Peel HuntReiterated RatingBuy
5/1/2020Peel HuntReiterated RatingBuy
4/24/2020Peel HuntReiterated RatingBuy
4/15/2020Liberum CapitalLower Price TargetBuyGBX 970 ➝ GBX 900
4/15/2020Peel HuntReiterated RatingBuy
4/3/2020Peel HuntReiterated RatingBuy
3/25/2020Berenberg BankLower Price TargetBuyGBX 920 ➝ GBX 750
3/20/2020Royal Bank of CanadaUpgradeOutperformGBX 800 ➝ GBX 730
3/18/2020Liberum CapitalReiterated RatingBuy
3/5/2020Peel HuntReiterated RatingBuy
2/5/2020Peel HuntReiterated RatingBuy
1/28/2020Liberum CapitalReiterated RatingBuy
1/27/2020Peel HuntReiterated RatingBuy
1/21/2020BarclaysBoost Price TargetOverweightGBX 830 ➝ GBX 910
1/21/2020Jefferies Financial GroupBoost Price TargetHoldGBX 620 ➝ GBX 735
1/20/2020Berenberg BankUpgradeBuyGBX 850 ➝ GBX 920
1/10/2020Liberum CapitalReiterated RatingBuy
1/10/2020Peel HuntReiterated RatingBuy
1/7/2020BarclaysReiterated RatingOverweight
12/17/2019Peel HuntReiterated RatingBuy
12/17/2019Liberum CapitalReiterated RatingBuy
12/6/2019Liberum CapitalReiterated RatingBuy
12/5/2019Peel HuntReiterated RatingBuy
11/26/2019Liberum CapitalReiterated RatingBuy
11/25/2019Peel HuntReiterated RatingBuy
11/21/2019BarclaysReiterated RatingOverweightGBX 830
11/15/2019Liberum CapitalReiterated RatingBuy
11/4/2019Peel HuntReiterated RatingBuy
9/2/2019Peel HuntReiterated RatingBuy
8/20/2019Berenberg BankBoost Price TargetHoldGBX 700 ➝ GBX 850
8/12/2019Royal Bank of CanadaDowngradeSector PerformerGBX 830 ➝ GBX 800
8/7/2019Peel HuntReiterated RatingBuy
8/7/2019Liberum CapitalReiterated RatingBuy
8/1/2019Peel HuntReiterated RatingBuy
7/26/2019Peel HuntReiterated RatingBuy
7/3/2019Peel HuntReiterated RatingBuy
6/4/2019Peel HuntBoost Price TargetBuyGBX 1,030 ➝ GBX 1,165
5/21/2019Liberum CapitalReiterated RatingBuy
5/20/2019Peel HuntReiterated RatingBuy
5/16/2019Numis SecuritiesUpgradeHold
5/13/2019Peel HuntReiterated RatingBuy
5/2/2019Peel HuntReiterated RatingBuy
4/4/2019BarclaysUpgradeOverweightGBX 770 ➝ GBX 720
4/2/2019Peel HuntReiterated RatingBuy
3/12/2019Peel HuntReiterated RatingBuy
2/4/2019Liberum CapitalReiterated RatingBuyGBX 884
1/29/2019Liberum CapitalReiterated RatingBuy
1/29/2019Peel HuntReiterated RatingBuy
1/11/2019Jefferies Financial GroupDowngradeHoldGBX 765 ➝ GBX 620
1/8/2019Liberum CapitalReiterated RatingBuy
1/7/2019Peel HuntReiterated RatingBuyGBX 1,105 ➝ GBX 1,030
12/14/2018Jefferies Financial GroupLower Price TargetBuyGBX 890 ➝ GBX 765
12/6/2018Peel HuntReiterated RatingBuy
11/27/2018Berenberg BankReiterated RatingHoldGBX 750
11/27/2018Numis SecuritiesReiterated RatingHoldGBX 660
11/27/2018Peel HuntReiterated RatingBuy
11/22/2018Liberum CapitalReiterated RatingBuy
11/7/2018Royal Bank of CanadaInitiated CoverageOutperformGBX 800
11/1/2018Peel HuntReiterated RatingBuy
10/3/2018Peel HuntReiterated RatingBuy
9/28/2018BarclaysReiterated RatingEqual weight
9/4/2018Peel HuntReiterated RatingBuy
8/24/2018Peel HuntReiterated RatingBuy
8/9/2018Jefferies Financial GroupUpgradeBuyGBX 895 ➝ GBX 890
8/8/2018Numis SecuritiesReiterated RatingReduce
8/8/2018Peel HuntReiterated RatingBuy
8/8/2018Liberum CapitalReiterated RatingBuyGBX 884
8/1/2018Peel HuntReiterated RatingBuy
7/3/2018Liberum CapitalReiterated RatingBuy
7/3/2018Numis SecuritiesReiterated RatingReduce
7/3/2018Peel HuntReiterated RatingBuy
6/18/2018Liberum CapitalReiterated RatingBuyGBX 884
6/6/2018Berenberg BankBoost Price TargetHoldGBX 815 ➝ GBX 850
5/31/2018Peel HuntReiterated RatingBuy
5/22/2018Peel HuntReiterated RatingBuy
5/22/2018Liberum CapitalReiterated RatingBuy
5/17/2018Numis SecuritiesReiterated RatingReduceGBX 765
5/17/2018BarclaysInitiated CoverageEqual WeightGBX 875
5/1/2018Peel HuntReiterated RatingBuy
4/17/2018Peel HuntUpgradeBuy
4/4/2018Peel HuntReiterated RatingAdd
2/23/2018Peel HuntReiterated RatingAddGBX 880
2/7/2018Libertas PartnersUpgradeBuyGBX 884
2/7/2018N+1 SingerReiterated RatingHoldGBX 813
2/7/2018Liberum CapitalUpgradeBuyGBX 884
2/1/2018Peel HuntReiterated RatingAddGBX 880
1/30/2018Numis SecuritiesReiterated RatingReduceGBX 765
1/30/2018Liberum CapitalReiterated RatingHoldGBX 884
1/17/2018Jefferies Financial GroupReiterated RatingHoldGBX 820
12/19/2017Peel HuntReiterated RatingAddGBX 880
12/7/2017Peel HuntBoost Price TargetAddGBX 860 ➝ GBX 880
12/4/2017Jefferies Financial GroupLower Price TargetHoldGBX 855 ➝ GBX 800
11/30/2017Stifel NicolausReiterated RatingHoldGBX 815
11/28/2017Liberum CapitalReiterated RatingHoldGBX 884
11/28/2017N+1 SingerReiterated RatingHold
11/28/2017Peel HuntReiterated RatingAddGBX 860
11/15/2017Liberum CapitalReiterated RatingHoldGBX 884
11/9/2017Numis SecuritiesDowngradeReduceGBX 765
11/1/2017N+1 SingerBoost Price TargetHoldGBX 770 ➝ GBX 841
10/31/2017Peel HuntBoost Price TargetAddGBX 840 ➝ GBX 860
10/4/2017Jefferies Financial GroupBoost Price TargetHoldGBX 830 ➝ GBX 855
8/15/2017N+1 SingerReiterated RatingHoldGBX 770
8/14/2017Numis SecuritiesReiterated RatingHoldGBX 765
8/14/2017Liberum CapitalDowngradeHoldGBX 930 ➝ GBX 884
8/10/2017Jefferies Financial GroupBoost Price TargetHoldGBX 785 ➝ GBX 830
8/10/2017Peel HuntReiterated RatingAddGBX 840
8/3/2017Numis SecuritiesReiterated RatingHoldGBX 730
8/3/2017Stifel NicolausReiterated RatingHoldGBX 775
8/3/2017Jefferies Financial GroupReiterated RatingHoldGBX 785
8/3/2017Liberum CapitalReiterated RatingBuyGBX 930
8/3/2017Peel HuntReiterated RatingAddGBX 830
8/3/2017N+1 SingerReiterated RatingHold
7/18/2017Liberum CapitalReiterated RatingBuyGBX 930
7/12/2017Liberum CapitalReiterated RatingBuyGBX 930
(Data available from 7/3/2017 forward)

News Sentiment Rating

0.78 (Buy)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
12/5/2021
  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
1/4/2022
  • 0 very positive mentions
  • 3 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
2/3/2022
  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
3/5/2022
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
4/4/2022
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
5/4/2022
  • 2 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
6/3/2022
  • 1 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
7/3/2022

Current Sentiment

  • 1 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

  • No negative mentions tracked during this time.
UDG Healthcare logo
UDG Healthcare plc, together with its subsidiaries, provides advisory, communication, commercial, clinical, and packaging services in the Republic of Ireland, the United Kingdom, North America, and internationally. The company operates in two segments, Ashfield and Sharp. The Ashfield segment offers commercialization services for the pharmaceutical and healthcare industry in the areas of advisory, communications, and commercial and clinical services. This segment supports healthcare professionals and patients at various stages of the product life cycle; and provides field and contact center sales teams, healthcare communications, patient support, audit, advisory, medical information, and event management services to approximately 300 healthcare companies. The Sharp segment provides contract and clinical trial packaging services for the pharmaceutical and biotechnology industries; serialization solutions; and clinical IRT services. The company was formerly known as United Drug plc and changed its name to UDG Healthcare plc in August 2013. UDG Healthcare plc was founded in 1948 and is heaquartered in Dublin, the Republic of Ireland.
Read More

Today's Range

Now: N/A

50 Day Range

MA: GBX 1,079
Low: 1,079
High: 1,079

52 Week Range

Now: N/A

Volume

N/A

Average Volume

1,385,642 shs

Market Capitalization

£2.72 billion

P/E Ratio

42.48

Dividend Yield

1.17%

Beta

N/A

Frequently Asked Questions

What sell-side analysts currently cover shares of UDG Healthcare?

The following Wall Street analysts have issued research reports on UDG Healthcare in the last year: Barclays PLC.
View the latest analyst ratings for UDG.

What is the current price target for UDG Healthcare?

0 Wall Street analysts have set twelve-month price targets for UDG Healthcare in the last year. Their average twelve-month price target is GBX 1,000.
View the latest price targets for UDG.

What is the current consensus analyst rating for UDG Healthcare?

UDG Healthcare currently has 1 hold rating from Wall Street analysts. The stock has a consensus analyst rating of "Hold." A "hold" rating indicates that analysts believe investors should keep any existing positions they have in UDG, but not buy more shares or sell existing shares.
View the latest ratings for UDG.

How do I contact UDG Healthcare's investor relations team?

UDG Healthcare's physical mailing address is River Walk 20, DUBLIN,, Ireland. The company's listed phone number is +353-1-4689000. The official website for UDG Healthcare is www.udghealthcare.com. Learn More about contacing UDG Healthcare investor relations.